Management of metabolic-associated fatty liver disease: The diabetology perspective

doi:10.3748/wjg.v29.i1.126

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 29, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5162)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-3) series, Tables (1-1) series.

Item

Count

PDF

295

WORD

HTML

3439

Figures (1-3)

267

Tables (1-1)

233

Sum=4275

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

224

Download

200

Sum=424

Publishing Process of This Article

Item

Count

Browse

185

Download

278

Sum=463

Jan 7, 2023 (publication date) through Apr 26, 2024

Times Cited of This Article

Times Cited (12)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Gastroenterol. Jan 7, 2023; 29(1): 126-143
Published online Jan 7, 2023. doi: 10.3748/wjg.v29.i1.126

Full Size Figure Download Figure

Figure 2 Major sites of action of drugs currently used in the treatment of metabolic-associated fatty live disease. Various medications targeting comorbidities that coexist with metabolic-associated fatty live disease are used to treat symptomatic patients. The asterisk indicates adipocyte action is not shown. GLP-1RA: Glucagon-like insulinotropic peptide-1 receptor agonist; SGLT-2: Sodium glucose cotransporter-2.

Citation: Jeeyavudeen MS, Khan SKA, Fouda S, Pappachan JM. Management of metabolic-associated fatty liver disease: The diabetology perspective. World J Gastroenterol 2023; 29(1): 126-143
URL: https://www.wjgnet.com/1007-9327/full/v29/i1/126.htm
DOI: https://dx.doi.org/10.3748/wjg.v29.i1.126